Approved Sickle Cell Drug Fails to Beat Placebo in Trial

You May Be Interested In:Boeing jet returns to US from China amid tariff war



(MedPage Today) — Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.
Adjusted annualized rate of vaso-occlusive crises leading to healthcare visits was 2.49 with the standard…

share Paylaş facebook pinterest whatsapp x print

Similar Content

A photo of a Kaiser Permanente medical facility.
Kaiser Permanente Back in the Hot Seat Over Mental Health Care, but It’s Not Only a KP Issue – KFF Health News
Allergy medications: Know your options
Coughing up blood
Women's Health Investment Reaps High Return, Report Suggests
US FDA Puts Clinical Hold on Atara’s Trials for Cancer Cell Therapies
Radiographic PFS in Metastatic CRPC More Than Doubles With Novel Combination
Radiographic PFS in Metastatic CRPC More Than Doubles With Novel Combination
A colorful mural spells out the word "HAVANA" on the side of a building.
Doctor Wanted: Small Town Offers Big Perks To Attract a Physician – KFF Health News
A photo of a broken bar of dark chocolate.
New Study Teases Out Chocolate and Diabetes Connection
The News Link | © 2025 | News